SATURN Transcatheter Mitral Valve Replacement for Functional Mitral Regurgitation

NCT ID: NCT04464876

Last Updated: 2024-05-22

Basic Information

• Recruitment Status: ACTIVE_NOT_RECRUITING
• Clinical Phase: NA
• Total Enrollment: 20 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2020-08-19
• Study Completion Date: 2024-12-31

Brief Summary

This study is a prospective, single-arm, multi-center feasibility clinical study of the SATURN TA System for the treatment of NYHA Class ≥ II patients with severe functional mitral regurgitation who are not suitable for surgical treatment following Heart Team assessment.

Conditions

Mitral Regurgitation; Valve Heart Disease; Heart Valve Diseases; Mitral Valve Disease; Mitral Disease

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Treatment

SATURN TA TMVR Device implanted

Group Type: EXPERIMENTAL

SATURN TA System

Intervention Type: DEVICE

SATURN TA TMVR Device implanted

Interventions

SATURN TA System

SATURN TA TMVR Device implanted

Intervention Type: DEVICE

Eligibility Criteria

Inclusion Criteria

1. Age 18 years or older.

2. Severe functional mitral regurgitation (≥ Grade 3+).

3. NYHA functional Class ≥ II. If Class IV, patient must be ambulatory.

4. Treatment and compliance with optimal guideline-directed medical therapy (GDMT) for heart failure for at least 30 days.

5. Not a suitable candidate for open mitral valve surgery due to high operative risk, as determined by the Heart Team.

6. Able to complete quality-of-life assessment (KCCQ).

Exclusion Criteria

1. Excessive frailty or comorbid conditions that preclude the anticipated benefit of the valve replacement.

2. Life expectancy <1 yr due to noncardiac conditions.

3. Active endocarditis.

4. Active systemic infection.

5. Modified Rankin Scale ≥4 disability.

6. Hemodialysis/ chronic renal failure (eGFR < 35 mL/min/m2).

7. Pulmonary arterial hypertension (fixed PAS < 60mmHg). 8) COPD on home oxygen.

9) Refuses blood transfusions. 10) Documented bleeding or coagulation conditions (hypo- or hyper-coagulable states).

11) Severe connective tissue disease under chronic immunosuppressive or cortisone therapy.

12) Pregnant/ lactating. Females of childbearing age must be willing to take contraceptives.

13) Participating in other investigational studies likely to confound the results or affect the study.

14) Unable to consent. 15) Unable or unwilling to comply with study Follow-up. 16) Patients classified as "vulnerable patients".

1. Myocardial infarction during prior 30 days.

2. Stroke or TIA during prior 30 days.

3. Severe extracardiac arteriopathy (safety measure for extra-circulatory support if surgical conversion is needed).

4. Prior mitral valve treatment (e.g. valve repair or replacement, MitraClip, etc.), and/or anticipated mitral valve treatment prior to enrollment.

5. Prior surgical mechanical valve AVR.

6. Prior TAVI.

7. Need for any cardiovascular surgery or intervention (other than for MV disease) within 30 days.

8. CRT or ICD implanted in previous 30 days.

9. Cardiogenic shock, hemodynamic instability, Systolic Blood Pressure <90mmHg, Inotropic dependent or IABP/mechanical circulatory support.

10. CABG or PCI within previous 30 days.

11. Adequately treated for cardiac condition per applicable standards, such as for coronary artery disease, left ventricular dysfunction, mitral regurgitation, or heart failure. No need for revascularization.

12. Prior or planned heart transplantation (UNOS status 1).

13. Physical evidence of right-sided congestive heart failure:

1. Patients with ascites.

2. Patients with anasarca (generalized edema / hydropsy).

14. Chest condition that prevents transapical access.

15. Known hypersensitivity or contraindication to procedural or post-procedural medication (e.g., contrast solution, anticoagulation therapy).

16. Documented hypersensitivity to nickel or titanium.

1. Left ventricular EF ≤ 30% by imaging.

2. Severe mitral annular calcification, severe mitral stenosis, valvular vegetation or mass.

3. Extensive mitral flail leaflets.

4. Left ventricular thrombus, mass, or vegetation.

5. Left ventricular end-diastolic diameter > 7.5 cm.

6. Severe right ventricular dysfunction.

7. Significant intracardiac shunt.

8. Anatomic ineligibility for SATURN valve as determined by the Screening Committee.

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

InnovHeart

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Marie Steinbrink

Role: STUDY_DIRECTOR

InnovHeart

Locations

Rigshospitalet University Hospital of Copenhagen

Copenhagen, , Denmark

Heart And Vascular Center, Semmelweis University

Budapest, , Hungary

Vilnius University Hospital Santaros klinikos

Vilnius, , Lithuania

Countries

Denmark; Hungary; Lithuania

Other Identifiers

TP-0050

Identifier Type: -

Identifier Source: org_study_id